For research use only. We do not sell to patients.

Risedronic acid sodium

CAS No. : 115436-72-1

Biological Activity：Risedronic acid sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.
Target:
Risedronic acid sodium, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronic acid sodium is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy [1].
The administration of 20 and 25 mg/kg Risedronic acid sodium for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with Risedronic acid sodium, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls [2].
Clinical indications: Bone resorption; Male osteoporosis; Osteogenesis imperfecta; Osteoporosis; Pagets bone disease
Toxicity: abdominal pain; anxiety, back pain; belching, bladder irritation; bone disorders and pain; bronchitis; bursitis; cataracts; chest pain; colitis; constipation; depression; diarrhea; difficulty breathing

Research Area：Others

Targets：Others

Related Screening Libraries:Drug Repurposing Compound Library Plus;FDA-Approved Drug Library Plus;FDA-Approved Drug Library Mini;Bioactive Compound Library Plus;FDA-Approved Drug Library;Drug Repurposing Compound Library;Anti-COVID-19 Compound Library;NMPA-Approved Drug Library;FDA Approved & Pharmacopeial Drug Library;Drug-Induced Liver Injury (DILI) Compound Library;

Related Small Molecules:Immune initiator-1;Obiltoxaximab;DIBAC-GGFG-NH2CH2-Dxd;Cyanine5.5 maleimide chloride;Cymarin;Z-Glycine;2-Deoxy-2-fluoro-D-glucose-13C,d7;Water-18O;Fmoc-N-Me-D-Ala-OH;3,5-Diiodo-L-tyrosine;N3-Pen-Dde;Zimeldine-d6;Ornidazole diol;Nylidrin hydrochloride;PFI-653;N-Arachidonoyl Taurine-d4;OVA Peptide (323-339);((3-Fluorophenyl)sulfonyl)glycine;7ß-Hydroxycholesterol-d7;MALAT1-IN-1;Sibiricose A1;Mefruside-d3;Ethacrynic acid mercapturate-d3;FLAG peptide;Neocurdione

About Us:

MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use；
Structurally and synthetically diverse biologically active compounds；
roduct quality is the key to our success and we take pride in offering only the highest-grade products.；
We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.；
Product identity, quality, purity and activity are assured by our robust quality control programs and procedures.；

Structurally and synthetically diverse biologically active compounds；

Customized order volume ranging from milligrams to kilograms scale；

We provide customer-oriented services. To explore more, please contact us at [email protected]. Our team will gladly assist you.

Top Publications Citing Use of MCE Products